JPMorgan analyst Richard Vosser raised the firm’s price target on Roche (RHHBY) to CHF 230 from CHF 220 and keeps an Underweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Genentech to present new data from Alzheimer’s development portfolio
- Roche plans to test if new medicine can prevent AD symptoms, Bloomberg says
- Roche says will work with EMA on path forward for Elevidys
- European Union committee recommends against Sarepta’s Elevidys
- Brazil suspends sales of Sarepta’s Elevidys after deaths